Medicines

Medicines that contribute to improving health worldwide.

Our medicines aim to improve patients’ lives

AstraZeneca is responding to a changing world and an increasing burden of disease by advancing one of the strongest and most productive pipelines in our industry and working to deliver life-changing medicines to patients around the world.

In Switzerland, AstraZeneca has a broad portfolio of prescription drugs in the following therapeutic areas

Cardiovascular disease

BRILIQUE

CRESTASTATIN

CRESTOR

INDERAL

PEMZEK

PEMZEK PLUS

PLENDIL 5 MG/10 MG/SENIOR 2,5 MG

TENORETIC/- MITE

TENORMIN/- MITE/- SUBMITE

ZESTORETIC/- MITE

ZESTRIL

You can find specialist and patient information at www.swissmedicinfo.ch

 

Diabetes

BYDUREON
 

BYETTA
 

FORXIGA
 

KOMBIGLYZE XR
 

ONGLYZA
 

QTERN
 

XIGDUO XR
 

You can find specialist and patient information at www.swissmedicinfo.ch

 

Oncology

CASODEX
 

FASLODEX
 

IMFINZI
 

IRESSA
 

LYNPARZA 50 MG KAPSELN
 

LYNPARZA FILMTABLETTEN
 

NOLVADEX
 

TAGRISSO
 

ZOLADEX
 

ZOLADEX LA
 

You can find specialist and patient information at www.swissmedicinfo.ch

 

Respiratory

ALVESCO, DOSING AEROSOL
 

BRICANYL TURBUHALER
 

DAXAS
 

EKLIRA GENUAIR
 

FASENRA
 

OXIS 6/12 TURBUHALER
 

PULMICORT
 

RHINOCORT, TURBUHALER
 

SYMBICORT
 

SYNAGIS  

VANNAIR 100/6, 200/6  

You can find specialist and patient information at www.swissmedicinfo.ch

 

Central nervous system

SEQUASE XR
 

SEQUASE
 

SEROQUEL XR
 

SEROQUEL
 

You can find specialist and patient information at www.swissmedicinfo.ch

 

Patient Safety

Patient safety is a top priority for AstraZeneca. That's why we review, document and analyse all information about adverse events and adverse reactions worldwide. Our aim is to monitor known risks and to identify unknown risks as quickly as possible and provide immediate information.

Help us by reporting side effects and adverse events!

 

Reporting side effects or adverse events

Tel.: +41 41 725 77 77

E-Mail

Reporting form

Online

We need at least the following information:

  • Which AstraZeneca drug was used?
  • What event was observed?
  • Who is affected? (Initials, sex, age of the patient)
  • Contact details of the reporting person for further inquiries

Reporting product complaints

Tel.: +41 41 725 75 75

E-Mail

Online

CH-2335; 03/2020